- Combination Therapy
BCL-2 (B-cell lymphoma 2) Inhibitor Market was valued at USD 1,657.8 million in 2022, growing at a 12.9% CAGR from 2023 to 2029. BCL-2 is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2 inhibitor BCL201 binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. With the rising prevalence of haematological cancer worldwide the demand for B-cell lymphoma 2 (Bcl-2) increased.
According to the leukemic & Lymphoma Society, approximately every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma, or myeloma, an estimated combined total of 186,400 people in the US are expected to be diagnosed with leukemia, lymphoma, or myeloma in 2021, new cases of leukemia, lymphoma and myeloma are expected to account for 9.8 percent of the estimated 1,898,160 new cancer cases that will be diagnosed in the US in 2021, the large number from the journal shows high extensive for B-cell lymphoma 2 (Bcl-2) inhibitors which drives the market. The increasing population of geriatric patients worldwide has escalated the BCL-2 market; drugs reached a large stage of development gradually impacting on growth of the market consequences resulting in lucrative opportunities in the market. Pharmaceutical companies and research organizations are continuously growing on novel drug development, but government regulations and clinical trials approval hinder the market growth which become major restraints in the B-cell lymphoma 2 (Bcl-2) inhibitor market. Geographically, North America held the major market share in 2022 and is expected to dominate the global BCL-2 market in the forecasted years due to global key players in this region.
Fastest Growing Market
The increasing prevalence of hematological diseases across the world is the major market driver in the BCL-2 Inhibitor Market during the forecast period. Blood cancer has become common among geriatric patients because it affects blood cells. Leukemia, lymphoma, and myeloma are some of the most common types of blood cancer. With the advanced development of novel drugs and continued approach towards health awareness in public about blood cancers, BCL-2 inhibitor drugs such as venetoclax and navitoclax selectively induce apoptosis in malignant cells reducing the risk factor, also increasing the demand for such drugs in the market which drives the market growth with significant growth.
The BCL-2 Inhibitor Market size was valued at USD 1,657.8 million in 2022.
The BCL-2 Inhibitor Market is poised to grow at a significant CAGR of 12.9% from 2022 to 2028.
The leading players in the BCL-2 Inhibitor Market are Abcam plc, Amgen Inc., Novartis AG, Santa Cruz Biotechnology Inc., Seagen Inc., Servie, Biorbyt Ltd., Ascentage Pharma Group International, AstraZeneca Plc, BeiGene Ltd., Bio-Techne Corp., Biorbyt Ltd., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Ipsen Pharma, and Merck & Co. Inc.